BR112021013415A2 - Proteínas de fusão multifuncionais e usos das mesmas - Google Patents

Proteínas de fusão multifuncionais e usos das mesmas

Info

Publication number
BR112021013415A2
BR112021013415A2 BR112021013415A BR112021013415A BR112021013415A2 BR 112021013415 A2 BR112021013415 A2 BR 112021013415A2 BR 112021013415 A BR112021013415 A BR 112021013415A BR 112021013415 A BR112021013415 A BR 112021013415A BR 112021013415 A2 BR112021013415 A2 BR 112021013415A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
multifunctional fusion
multifunctional
fusion protein
administering
Prior art date
Application number
BR112021013415A
Other languages
English (en)
Portuguese (pt)
Inventor
Romeo Smith Carmella
L Tykocinski Mark
C Weber Matthew
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of BR112021013415A2 publication Critical patent/BR112021013415A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021013415A 2019-01-07 2020-01-07 Proteínas de fusão multifuncionais e usos das mesmas BR112021013415A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789212P 2019-01-07 2019-01-07
PCT/US2020/012624 WO2020146423A1 (en) 2019-01-07 2020-01-07 Multi-functional fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112021013415A2 true BR112021013415A2 (pt) 2021-12-28

Family

ID=71521906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021013415A BR112021013415A2 (pt) 2019-01-07 2020-01-07 Proteínas de fusão multifuncionais e usos das mesmas

Country Status (12)

Country Link
US (1) US12497439B2 (https=)
EP (1) EP3908664A4 (https=)
JP (1) JP7587505B2 (https=)
KR (1) KR20220025698A (https=)
CN (1) CN113518823B (https=)
AU (1) AU2020207265B2 (https=)
BR (1) BR112021013415A2 (https=)
CA (1) CA3125748A1 (https=)
IL (1) IL284679A (https=)
MX (1) MX2021008207A (https=)
SG (1) SG11202107454UA (https=)
WO (1) WO2020146423A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3820887A4 (en) 2018-07-11 2022-04-20 KAHR Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
EP3908664A4 (en) 2019-01-07 2023-01-25 Thomas Jefferson University MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES
CN116261567A (zh) * 2020-07-03 2023-06-13 纽约市哥伦比亚大学理事会 多功能性正交蛋白嵌合体
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
WO2022188129A1 (zh) * 2021-03-12 2022-09-15 利时雨 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用
AU2023253516A1 (en) * 2022-04-15 2024-11-21 Imbiologics Corp. Fusion protein platform with improved half-life

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220482A1 (en) 2000-02-03 2003-11-27 Ziwei Huang Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II
WO2002022687A2 (en) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
CA2448109A1 (en) 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2014121085A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
JP2018516969A (ja) * 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
CA3004804A1 (en) * 2015-11-17 2017-05-26 Jiangsu Hengrui Medicine Co., Ltd. Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
US20200093789A1 (en) 2017-05-10 2020-03-26 The General Hospital Corporation Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
EP3626266A4 (en) * 2017-05-16 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
GB201709808D0 (en) * 2017-06-20 2017-08-02 Kymab Ltd Antibodies
AR112257A1 (es) * 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
EP3908664A4 (en) 2019-01-07 2023-01-25 Thomas Jefferson University MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES

Also Published As

Publication number Publication date
KR20220025698A (ko) 2022-03-03
CN113518823A (zh) 2021-10-19
US12497439B2 (en) 2025-12-16
AU2020207265A1 (en) 2021-08-12
IL284679A (en) 2021-08-31
EP3908664A4 (en) 2023-01-25
US20220056102A1 (en) 2022-02-24
CA3125748A1 (en) 2020-07-16
JP2022528030A (ja) 2022-06-08
CN113518823B (zh) 2025-05-02
EP3908664A1 (en) 2021-11-17
AU2020207265B2 (en) 2026-03-26
WO2020146423A1 (en) 2020-07-16
SG11202107454UA (en) 2021-08-30
JP7587505B2 (ja) 2024-11-20
MX2021008207A (es) 2021-11-04

Similar Documents

Publication Publication Date Title
BR112021013415A2 (pt) Proteínas de fusão multifuncionais e usos das mesmas
BR112022008641A2 (pt) Métodos de tratamento com modulador de miosina
MX2020008455A (es) Variantes de il-15 y usos de las mismas.
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
NI201100077A (es) Terapia de combinación con epoxicetonas peptídicas.
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
MX2024005705A (es) Composiciones de liquidos ionicos.
BR112015022257A2 (pt) uso de uma proteína de fusão de hormônio de crescimento humano-xten (hgh-xten), dose em bolus pediátrica de uma proteína de fusão hgh-xten e kit
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
AR103118A1 (es) Tratamientos médicos basados en anamorelina
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2019006444A (es) Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
EA202191686A1 (ru) Гидролизат коллагена для применения против кожных болезней и кишечных заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
IL290891A (en) Compositions and methods of treating vascular diseases
BR112023019488A2 (pt) Colágeno tipo ii recombinante para uso terapêutico
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
BR112017002083A2 (pt) sistema de bioprocessamento de microescala e método para fabricação de proteína de sangue humano
BR112022004475A2 (pt) Proteínas de fusão nkg2d e usos das mesmas